Cargando…
New onset severe ulcerative colitis following Ixekizumab therapy
Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic...
Autores principales: | Morosanu, Alina Mihaela, Mihai, Ioana Ruxandra, Rezus, Ioana Irina, Gavrilescu, Otilia, Dranga, Mihaela, Prelipcean, Cristina Cijevschi, Mihai, Catalina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
UMF “Gr. T. Popa” Iasi Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/ https://www.ncbi.nlm.nih.gov/pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 |
Ejemplares similares
-
Laboratory Data and IBDQ—Effective Predictors for the Non-Invasive Machine-Learning-Based Prediction of Endoscopic Activity in Ulcerative Colitis
por: Gavrilescu, Otilia, et al.
Publicado: (2023) -
Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients
por: Gavrilescu, Otilia, et al.
Publicado: (2022) -
Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
por: Mihai, Ioana Ruxandra, et al.
Publicado: (2023) -
Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention
por: Jucan, Alina Ecaterina, et al.
Publicado: (2022) -
Extrapancreatic necrosis volume: A new tool in acute pancreatitis severity assessment?
por: Cucuteanu, Bogdan, et al.
Publicado: (2021)